Avtal | $24,000,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Certified by Founder
Lodge
CellFE
start up
United States
- Alameda, California
- 28/09/2023
- Series A
- $22,000,000
CellFE is a cell engineering startup that enables development and manufacturing of the new generation of medicines – cell therapies. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering –efficiently delivering gene-editing molecules into cells while preserving cell viability. CellFE’s technology:
• Enables development of previously inaccessible cell therapies by providing means for transporting hard-to-deliver molecules into the cells.
• Accelerates commercialization of existing cell therapies by significantly reducing cost, complexity, and processing time, while improving the efficacy and safety of the cell engineering process.
- Industry Biotechnology
- Website https://www.cellfebiotech.com/
- LinkedIn https://www.linkedin.com/company/cellfe-biotech/about/
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)